All News

Your daily dose of the clinical news you may have missed.

A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.

As authorities record data on the largest US measles outbreak in decades, 79% of Americans support school vaccine mandates for children, an encouraging result.

The StateViewer clinical decision support system could help expand access to specialist-level insights in clinics that lack neurology expertise, according to researchers.

Back pain is more common in the US than homeownership, but despite the prevalence, myths persist regarding origins, treatment, and prevention. Here are 8 of them.

Your daily dose of the clinical news you may have missed.

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.

Obesity treatment evolves as GLP-1 medication use surges 587%, while bariatric surgery rates decline significantly. A new analysis parses the trends.

July 4th invites celebration, typically with alcohol. Try our quiz based on a review of the holiday drinking patterns of US adults. Are answers to these 10 questions what you expect?

Your daily dose of the clinical news you may have missed.

The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Viking Therapeutics initiates phase 3 trials for VK2735, a promising dual incretin agonist targeting obesity and other metabolic disorders, based on strong phase 2 findings.